Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,591.00
Bid: 1,590.50
Ask: 1,591.50
Change: -27.00 (-1.67%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday newspaper round-up: De La Rue, Tesco, Glaxo Smith Kline

Mon, 23rd Jul 2018 06:40

(Sharecast News) - The hedge fund pushing for change at passport and banknote maker De La Rue has increased its stake and ramped-up pressure on the boss to overhaul the firm. Crystal Amber is now understood to control about 4 per cent of the British company, up from 3.1 per cent following a high volume of trades on Friday. The activist fund is calling on De La Rue's management to come up with a strategy that will prepare it for the future by focusing more on selling its technology. - The Daily MailTesco is set to launch a chain of discount shops to take on cut-price German retailers Aldi and Lidl at their own game. The supermarket giant has earmarked as many as 60 existing stores to transform into a low-price chain expected to operate under a new brand name. Sources speculated that the stores may be called Jack's - a reference to Tesco founder Jack Cohen - because an obscure Tesco subsidiary recently tried to register the name as a trademark. - The Daily MailIn a strategy update this week, Glaxo is expected to outline plans to focus on developing blockbuster cancer drugs as it rebuilds its portfolio in the medicines industry's most lucrative market four years after it largely, and contentiously, exited the area via a multibillion-dollar asset swap with Novartis, a Swiss rival. Ms Walmsley will be joined at a presentation to the City on Wednesday by Hal Barron, Glaxo's new chief scientific officer and head of research and development, who has been reviewing the drugs pipeline for the past six months. - The TimesTheresa May will chair a cabinet meeting in the north-east of England as she starts a summer campaign intended to gain public support for her much-criticised Chequers Brexit plan. The visit on Monday is intended primarily to show the government's ongoing support for the "northern powerhouse" concept, and May will confirm that up to £780m is being set aside for a pre-planned east coast mainline upgrade and that the is to go ahead. - The GuardianPresident Trump's efforts to neutralise the nuclear threat posed by North Korea are in danger of running aground as the communist state cancels key meetings and returns to its belligerent rhetoric. [...] However, US diplomats have since made it known that their counterparts in Pyongyang have refused to engage in meaningful discussions. American intelligence officials have told The Washington Post that the North is working to conceal key aspects of its nuclear programme and that a missile-engine testing facility that Mr Trump said would be destroyed remains intact. - The TimesBritain will "thrive" even if there is no Brexit deal, Dominic Raab has said, as his predecessor David Davis called on the Prime Minister to "reset" her Brexit plan and prepare a "reserve parachute" in case no agreement is reached. Mr Raab said there was "tremendous pressure" on the EU to secure a deal as he branded his counterparts "irresponsible" for failing to reassure British citizens living abroad about their rights after Brexit. - The Daily TelegraphA second investment fund has been set up in Ireland by the City firm co-founded by Jacob Rees-Mogg, after it warned earlier this year about the financial dangers of the sort of hard Brexit favoured by the Conservative MP. The fund, which is backed by $50m (£38m) in seed money from the Swedish national pension plan, was created to meet demand from international investors, according to Somerset Capital Management (SCM). - The Guardian
More News
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 14:31

Zantac litigation fears overdone at GSK, says Shore Capital

(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.

Read more
11 Jun 2024 09:32

TOP NEWS: GSK takes first steps to appeal Zantac ruling in Delaware

(Alliance News) - GSK PLC on Tuesday said it has taken the first steps to seek appeal of a ruling by the Delaware Superior Court in regard to its discontinued heartburn drug Zantac.

Read more
11 Jun 2024 09:12

LONDON MARKET OPEN: FTSE 100 up; UK unemployment rises to 4.4%

(Alliance News) - Stock prices in London opened higher on Tuesday, after a difficult day for markets on Monday amid the EU election fallout.

Read more
11 Jun 2024 07:52

LONDON BRIEFING: FTSE 100 called up despite unemployment rise

(Alliance News) - The FTSE 100 in London was called to open higher on Tuesday, after data showed that unemployment in the UK unexpectedly rose.

Read more
11 Jun 2024 07:22

GSK launches appeal to recent Zantac ruling

(Sharecast News) - GSK has started the process of appealing a recent decision by the Delaware Superior Court regarding the ongoing Zantac, or ranitidine, litigation, it announced on Tuesday.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
10 Jun 2024 19:00

TOP NEWS: GSK welcomes dismissal of Zantac case in Illinois

(Alliance News) - GSK PLC on Monday welcomed the dismissal of a case in the US concerning the heartburn drug, Zantac, which was due to start on Monday.

Read more
10 Jun 2024 12:42

EU to secure 40 million avian flu vaccines for 15 countries - officials

BRUSSELS, June 10 (Reuters) - The EU will sign a contract on Tuesday to secure over 40 million doses of a preventative avian flu vaccine for 15 countries with the first shipments heading to Finland, EU officials said on Monday.

Read more
10 Jun 2024 08:39

GSK gets FDA approval for Arexvy vax in 50-59 year olds at risk of RSV

(Alliance News) - GSK PLC on Monday announced that the US Food & Drug Administration has approved an expanded age indication for its respiratory syncytial virus vaccine.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 07:17

GSK's Arexvy vaccine approved for wider age range

(Sharecast News) - US regulators have approved the use of GSK's Arexvy vaccine for a younger age group, the biopharma group announced on Monday.

Read more
7 Jun 2024 19:34

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.